

PRESS RELEASE

9 A.M. EDT, May 20, 2010

HEPTARES THERAPEUTICS EXTENDS MULTI-FTE CHEMISTRY COLLABORATION WITH OXYGEN HEALTHCARE (O2h)

Executives from Heptares Therapeutics (Welwyn Garden City, UK) and O2h (Cambridge, UK) announced today an extension of the agreement under which O2h provides multi-FTE -synthetic chemistry services to support discovery programmes at Heptares.

Dr. Miles Congreve, Head of Chemistry said, "We are happy to have signed this new contract with O2h; they have been a solid chemistry partner and have also supported us with some basic ADME, which helps to reduce discovery cycle times."

Sunil Shah, CEO, O2h "We have had a successful partnership with Heptares Therapeutics and are delighted at this extension for the third year. Heptares has a very innovative technology that we are happy to have supported since inception and believe will lead to new GPCR drugs being discovered."

About Oxygen Healthcare Ltd

O2h is a 5 year old discovery services company co-located in Cambridge, UK and Ahmedabad, India. The Indian operations provide a high level of chemistry expertise while UK office provides project management support. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based synthetic chemistry, medicinal chemistry, computational chemistry, full services lab-units and ADME. Further information on O2h can be found at www.o2h.com.

Contact information:

Dr. Ekta Ahuja

info@o2h.com

OXYGEN HEALTHCARE LTD

23 Cambridge Science Park

CB4 0EY

About Heptares Therapeutics

Heptares is a drug discovery company focused on identifying novel drug candidates targeting validated G-protein-coupled receptors (GPCRs) in several disease areas. Based on its unique StaR™ technology platform, Heptares has built an integrated drug discovery capability and aims to progress promising candidates internally and through strategic alliances.

GPCRs are the single most important family of drug targets in the human body, but because of their inherent instability they are refractory to structural studies and biochemical screening. StaR technology enables the engineering of stabilised GPCRs, making them amenable to these vital drug discovery approaches. There are many clinically relevant GPCR targets across a wide range of therapeutic areas where discovery is advancing slowly and for which structural information, novel screening approaches and potential antibody therapeutics would greatly enhance progress.

Heptares was founded in 2007 and its StaR technology arose out of the pioneering work of Heptares' founding scientists at the MRC Laboratory of Molecular Biology (Cambridge, UK) and the National Institute for Medical Research (London, UK).

For more information, see www.heptares.com

Contact Information:

Dr. Miles Congreve
Heptares Therapeutics
BioPark
Broadwater Road
Welwyn Garden City
Herts, AL7 3AX